Compare Agilent Technologies Inc (A) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs JPMorgan Chase & Co — how do they compare? Agilent Technologies Inc trades at $128.57 (market cap $37.04B), while JPMorgan Chase & Co trades at $331.85 (market cap $908.94B). The key difference: JPMorgan Chase & Co is far larger — about 24.5× Agilent Technologies Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.77%). Which is the better fit depends on your goals.
| A | JPM | |
|---|---|---|
Market Cap | $37.04B | $908.94B |
Sector | Health | Financials |
52-Week High | $157.20 | $339.22 |
52-Week Low | $110.24 | $282.78 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | 1.77% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
JPMorgan Chase (JPM) trades at $333.43, down 1.27% over the past day, with a P/E of 16.24 and P/B of 2.64. Recent earnings show mixed results, beating expectations in Q1 2026 but missing in Q4 2025. The stock exhibits a bullish technical trend, supported by strong moving averages and a consensus analyst price target of $360.38. Revenue grew to $181.85B in 2025, though net income dipped slightly to $57.05B. Institutional sentiment remains positive, with 51.67% of analysts rating it a Buy.
Outlook: JPMorgan's robust ROE of 17.03% and steady revenue growth support a favorable long-term view, but risks include geopolitical tensions, cybersecurity threats, and volatile cash flows. The stock presents a solid opportunity for value investors, though macroeconomic headwinds and interest rate sensitivity warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
